Perrigo Sets Strategy For Global Infant Formula Growth
This article was originally published in The Tan Sheet
The private labeler’s more than 60 planned product launches include Codex-compliant infant formulas. The firm also sees marketing formula in plastic containers as a U.S. sales driver.
You may also be interested in...
The private labeler sees about $115 billion worth of branded Rx products with potential to switch OTC, including statins and longer-shot switches for diabetes, hypertension and topical steroid drugs. Perrigo’s shorter-term pipeline includes equivalents of proton pump inhibitors Nexium, Protonix and Aciphex.
Perrigo takes the next step toward becoming a one-stop shop for private-label consumer health products with its $808 million acquisition of infant formula and baby food firm PBM Holdings Inc
Proposal for simultaneous Rx and OTC sales of same drug at same dose and indication has CHPA hoping FDA acknowledges Pataday and Voltaren Arthritis Relief are competing with Rx equivalents even though elimination of prescription NDAs was part of approvals for the two switches.